Lonza's Capsule Delivery Solutions Launches Capsugel® Colorista™

August 31, 2018
Offering a unique R&D solution for early-stage development and compatibility testing, Colorista™ capsules contain a broad selection of colorants suitable for use in major markets, allowing pharmaceutical customers to have access to a wide array of colors, and are available in both Vcaps® Plus (HPMC) and Coni-Snap® gelatin.

Basel (CH), 31 August 2018 – Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is launching the Capsugel® Coloristaproduct, a high-quality capsule based on an “all-colorants” formulation. This new capsule further expands the Lonza Capsugel® R&D offering.

Colorista capsules contain a broad selection of colorants suitable for use in major markets, allowing pharmaceutical customers to have access to a wide array of colors, and are available in both Vcaps® Plus (HPMC) and Coni-Snap® gelatin.

“A common issue faced by drug product developers is that the color composition choice for the commercial drug product is often made after initial stability studies. If new colors are introduced, it may require additional studies, which can result in costly delays," said Emmanuelle Saugues, Color Lab EMEA Supervisor for Lonza. "To address this problem, we have developed Coloristacapsules at the Capsugel® Color Lab.”  

Colorista capsules offer more than 150 color options in Coni-Snap® gelatin capsules and more than 50 color options in Vcaps® Plus capsules and are available in different sizes to enable the encapsulation of a wide range of doses and formulations.

Niki Kolokotronis, Sales Director Americas for Capsule Delivery Solutions, explained: “Colorista™ capsules meet the demand of our pharmaceutical customers who look for solutions that cut down on development time while giving them flexibility to progress with technical development before the final commercial color decision is taken.”

Like all other products in the Capsugel® portfolio, Coloristacapsules rely on Color Lab services, as well as regulatory and compliance support, to help Lonza’s customers in the formulation, design and manufacturing of high-quality oral delivery solutions.  

The addition of Colorista capsules broaden the already comprehensive pre-clinical and clinical portfolio of Capsugel® empty capsules, providing solutions for the full drug product development process.

More information about Capsugel Colorista™ capsules is available here.

About Lonza's Capsule Delivery Solutions

Capsule Delivery Solutions, part of Lonza Pharma Biotech, is the global leader in capsules and encapsulation technology and designs. Their unique combination of science, engineering, formulation and capsule expertise enables customers to optimize the bioavailability, targeted delivery and overall performance of their products. Capsule Delivery Solutions’ Capsugel® brand represents more than 85 years of experience, excellence and dedication to the pharmaceutical and nutraceutical industries. More information about the Capsugel® product range is available on www.capsugel.com.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Lonza Contact Information

Constance Ward, Head External Communications

Lonza Group Ltd

Tel +41 61 316 8840


Sara Lesina, Head of Global Marketing

Capsule Delivery Solutions

Tel + 32 38 90 0519


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.